Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast Cancer

December 11th 2024

Hope S. Rugo, MD, FASCO, discusses updated safety findings from the ELEVATE trial of elacestrant-based combinations in ER+/HER2– metastatic breast cancer.

Cilta-Cel Leads to 100% MRD-Negativity Rate in High-Risk Smoldering Multiple Myeloma

December 11th 2024

Cilta-cel without induction therapy in high-risk smoldering myeloma marked the first study of CAR T-cell therapy in a precursor cancer setting.

Dr Kaklamani on the Effects of VAF on Elacestrant Outcomes in ER+ Breast Cancer

December 11th 2024

Virginia Kaklamani, MD, DSc, discusses an analysis of ESR1 allelic frequencies in elacestrant-exposed ER+/HER2– metastatic ESR1-mutated breast cancer.

CAN-2409 Improves DFS in Intermediate/High-Risk Localized Prostate Cancer

December 11th 2024

CAN-2409 plus valacyclovir and radiation therapy significantly improved DFS in intermediate- to high-risk localized prostate cancer.

Dr Bardia on T-DXd Efficacy By Pace of Prior CDK4/6 Inhibitor Progression in Breast Cancer

December 11th 2024

Aditya Bardia, MD, MPH, FASCO, discusses the efficacy of T-DXd in HER2-low/ultralow metastatic breast cancer by disease progression on prior therapy.

IMNN-001 Plus Perioperative Chemotherapy Maintains OS Benefit in Newly Diagnosed Advanced Ovarian Cancer

December 10th 2024

After an additional 7 months of follow-up, IMNN-001 plus chemotherapy produced a 13-month increase in median OS in advanced ovarian cancer

Luveltamab Tazevibulin Produces Responses in Platinum-Resistant Ovarian Cancer

December 10th 2024

Luveltamab tazevibulin produced responses in patients with platinum-resistant ovarian cancer.

T-DXd Steadily Transforms the NSCLC Treatment Paradigm: With Misako Nagasaka, MD, PhD

December 10th 2024

Dr Nagasaka discusses the use of T-DXd in patients with unresectable or metastatic HER2-positive NSCLC.

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

December 9th 2024

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia

December 9th 2024

Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.

Pembrolizumab/Chemo, Followed by Olaparib Maintenance, Boosts PFS in Advanced Ovarian Cancer

December 9th 2024

Pembrolizumab plus chemotherapy, followed by olaparib with or without bevacizumab, improved PFS in advanced ovarian cancer.

FDA Grants Breakthrough Therapy Designation to Dato-DXd for Previously Treated EGFR+ Advanced NSCLC

December 9th 2024

The FDA granted breakthrough therapy designation to Dato-DXd for previously treated EGFR-mutated advanced non–small cell lung cancer.

JAK Inhibitors Remain Central to Advancing Care in Myelofibrosis

December 6th 2024

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis and how the use of this class of agents may evolve.

Revumenib Could Provide New Path to Transplant in R/R KMT2A+ Acute Leukemia

December 6th 2024

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib for relapsed/refractory acute leukemia with KMT2A rearrangements.

AdAPT-001 Gets FDA Fast Track Designation in Recurrent/Refractory Soft Tissue Sarcoma

December 6th 2024

AdAPT-001 plus nivolumab or atezolizumab has received fast track designation from the FDA in recurrent/refractory soft tissue sarcoma.

RP1 and Other Oncolytic Viruses Could Pave a New Treatment Pathway in Advanced Melanoma

December 6th 2024

Bently P. Doonan, MD, discusses the utility of oncolytic viruses and the need for novel treatments after checkpoint inhibitors in advanced melanoma.

FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer

December 6th 2024

The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

December 6th 2024

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Immunotherapy Reshapes Perioperative Strategies for Early NSCLC Without Driver Mutations

December 5th 2024

Roy S. Herbst, MD, explores evolving chemoimmunotherapy strategies for early-stage NSCLC that does not harbor actionable mutations.

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer

December 5th 2024

Monica H. Vetter, MD, discusses the integration of immunotherapy into chemotherapy regimens for frontline advanced endometrial cancer.